NGM’s NGM621 now looks like a dead end, but there are plenty of others hoping for a piece of this market, including Roche and Lineage.
GSK ends long-running work targeting NY-ESO-1, and that’s bad news for Adaptimmune as well as Lyell.
But the main question for deal-hungry investors will be what this means for the chances of Merck & Co buying out Seagen.
Failure of the company’s in-house lead raises questions about the viability of its extensively partnered probody technology.
Key upcoming clinical results approach in the third quarter for lecanemab, high-dose Eylea and Zimura.